科研之友
微信
新浪微博
Facebook
分享链接
摘要
Prostate cancers are among the common malignancies in men. Despite the availability of various treatment options, including chemotherapy, radiotherapy, and surgery, the prognosis for advanced prostate tumors remains poor. One of the major challenges in the therapy of prostate cancer is its resistance to conventional therapies. Therefore, there is a requirement to design new therapeutic approaches to enhance the efficacy of anticancer drugs and radiotherapy. In recent years, there has been growing interest in boosting anticancer immunity in various malignancies such as prostate cancer. This approach aims to target several immune interactions in the tumor microenvironment (TME) to enrich the immune system's capacity to identify and eradicate malignant cells. Therefore, understanding these interactions is essential for developing effective immunotherapeutic strategies for prostate cancer. Numerous approaches have been suggested to boost anticancer immunity in prostate cancer, consisting of immune checkpoint inhibitors (ICIs), cancer vaccines, adoptive cell therapy, cytokine-based therapies, adjuvant therapy, nanoparticles, and also targeting some other specific molecules. In the present paper, we will discuss the various approaches for boosting anticancer immunity in prostate cancer and likely therapeutic targets for reducing prostate cancer resistance to anticancer drugs and radiotherapy. We will also emphasize the limitations and forthcoming directions for developing effective immunotherapeutic strategies for prostate cancer.
